
Hisamitsu Pharmaceutical Co Inc
TSE:4530

Hisamitsu Pharmaceutical Co Inc?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3 636
4 656
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Hisamitsu Pharmaceutical Co Inc hold over its rivals?
What risks and challenges
does Hisamitsu Pharmaceutical Co Inc face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Hisamitsu Pharmaceutical Co Inc.
Provide an overview of the primary business activities
of Hisamitsu Pharmaceutical Co Inc.
What unique competitive advantages
does Hisamitsu Pharmaceutical Co Inc hold over its rivals?
What risks and challenges
does Hisamitsu Pharmaceutical Co Inc face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Hisamitsu Pharmaceutical Co Inc.
Provide P/S
for Hisamitsu Pharmaceutical Co Inc.
Provide P/E
for Hisamitsu Pharmaceutical Co Inc.
Provide P/OCF
for Hisamitsu Pharmaceutical Co Inc.
Provide P/FCFE
for Hisamitsu Pharmaceutical Co Inc.
Provide P/B
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/S
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/GP
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/EBITDA
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/EBIT
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/OCF
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/FCFF
for Hisamitsu Pharmaceutical Co Inc.
Provide EV/IC
for Hisamitsu Pharmaceutical Co Inc.
Show me price targets
for Hisamitsu Pharmaceutical Co Inc made by professional analysts.
What are the Revenue projections
for Hisamitsu Pharmaceutical Co Inc?
How accurate were the past Revenue estimates
for Hisamitsu Pharmaceutical Co Inc?
What are the Net Income projections
for Hisamitsu Pharmaceutical Co Inc?
How accurate were the past Net Income estimates
for Hisamitsu Pharmaceutical Co Inc?
What are the EPS projections
for Hisamitsu Pharmaceutical Co Inc?
How accurate were the past EPS estimates
for Hisamitsu Pharmaceutical Co Inc?
What are the EBIT projections
for Hisamitsu Pharmaceutical Co Inc?
How accurate were the past EBIT estimates
for Hisamitsu Pharmaceutical Co Inc?
Compare the revenue forecasts
for Hisamitsu Pharmaceutical Co Inc with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Hisamitsu Pharmaceutical Co Inc and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Hisamitsu Pharmaceutical Co Inc against its competitors.
Analyze the profit margins
(gross, operating, and net) of Hisamitsu Pharmaceutical Co Inc compared to its peers.
Compare the P/E ratios
of Hisamitsu Pharmaceutical Co Inc against its peers.
Discuss the investment returns and shareholder value creation
comparing Hisamitsu Pharmaceutical Co Inc with its peers.
Analyze the financial leverage
of Hisamitsu Pharmaceutical Co Inc compared to its main competitors.
Show all profitability ratios
for Hisamitsu Pharmaceutical Co Inc.
Provide ROE
for Hisamitsu Pharmaceutical Co Inc.
Provide ROA
for Hisamitsu Pharmaceutical Co Inc.
Provide ROIC
for Hisamitsu Pharmaceutical Co Inc.
Provide ROCE
for Hisamitsu Pharmaceutical Co Inc.
Provide Gross Margin
for Hisamitsu Pharmaceutical Co Inc.
Provide Operating Margin
for Hisamitsu Pharmaceutical Co Inc.
Provide Net Margin
for Hisamitsu Pharmaceutical Co Inc.
Provide FCF Margin
for Hisamitsu Pharmaceutical Co Inc.
Show all solvency ratios
for Hisamitsu Pharmaceutical Co Inc.
Provide D/E Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide D/A Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide Interest Coverage Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide Altman Z-Score Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide Quick Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide Current Ratio
for Hisamitsu Pharmaceutical Co Inc.
Provide Cash Ratio
for Hisamitsu Pharmaceutical Co Inc.
What is the historical Revenue growth
over the last 5 years for Hisamitsu Pharmaceutical Co Inc?
What is the historical Net Income growth
over the last 5 years for Hisamitsu Pharmaceutical Co Inc?
What is the current Free Cash Flow
of Hisamitsu Pharmaceutical Co Inc?
Discuss the annual earnings per share (EPS)
trend over the past five years for Hisamitsu Pharmaceutical Co Inc.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
JP |
![]() |
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
301.7B JPY | 9.9 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
779.4B USD | 42.8 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
394B USD | 13.1 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK | 13.7 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
236.5B CHF | 11.5 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
177B GBP | 126.9 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
225.9B USD | 8.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
199.7B CHF | 11.5 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD | 267.5 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.8B USD | 8.5 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
JP |
![]() |
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
Average EV/EBITDA:
396.4
9.9
|
19%
|
0.5 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
42.8
|
30%
|
1.4 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
13.1
|
7%
|
1.9 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
13.7
|
15%
|
0.9 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
11.5
|
8%
|
1.4 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
126.9
|
9%
|
14.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.9
|
9%
|
1 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
11.5
|
5%
|
2.3 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
267.5
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
8.5
|
3%
|
2.8 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.